natgillin/translations-raw huggingface dataset:
Aripiprazole havde bedre effekt end placebo ved ændring fra baseline ved uge 4 og ved uge 12 målt på total Y-MRS-score.
Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score.
Aripiprazole metaboliseres hovedsageligt i leveren via tre biotransformationsveje: dehydrogenering, hydroxylering og N-dealkylering.
Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation.
Aripiprazole metaboliseres via flere enzymsystemer, der involverer CYP2D6- og CYP3A4-enzymer, men ikke CYP1A-enzymer.
Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes.
Aripiprazole Mylan Pharma 10 mg tabletter
Aripiprazole Mylan Pharma 10 mg tablets
Aripiprazole Mylan Pharma 10 mg tabletter Aripiprazole
Aripiprazole Mylan Pharma 10 mg tablets aripiprazole
Aripiprazole Mylan Pharma 10 mg tabletter er lyserøde, runde og bikonvekse af 8,1 mm i diameter, indgraveret med "10" på den ene side.
Aripiprazole Mylan Pharma 10 mg tablets are pink, round and biconvex of 8.1mm in diameter, engraved with ‘10’ on one side.
Aripiprazole Mylan Pharma 10 mg tabletter EU/1/15/1005/004
Aripiprazole Mylan Pharma 10 mg tablets
Aripiprazole Mylan Pharma 10 mg tabletter Hver tablet indeholder 10 mg Aripiprazole.
Aripiprazole Mylan Pharma 10 mg tablets Each tablet contains 10 mg of aripiprazole.
Aripiprazole Mylan Pharma 15 mg tabletter
Aripiprazole Mylan Pharma 15 mg tablets
Aripiprazole Mylan Pharma 15 mg tabletter Aripiprazole
Aripiprazole Mylan Pharma 15 mg tablets aripiprazole
Aripiprazole Mylan Pharma 15 mg tabletter er gule, runde og bikonvekse af 10.1mm i diameter, præget "15" på den ene side.
Aripiprazole Mylan Pharma 15 mg tablets are yellow, round and biconvex of 10.1mm in diameter, engraved with ‘15’ on one side.
Aripiprazole Mylan Pharma 15 mg tabletter EU/1/15/1005/007
Aripiprazole Mylan Pharma 15 mg tablets
Aripiprazole Mylan Pharma 15 mg tabletter Hver tablet indeholder 15 mg Aripiprazole.
Aripiprazole Mylan Pharma 15 mg tablets Each tablet contains 15 mg of aripiprazole.
Aripiprazole Mylan Pharma 30 mg tabletter Aripiprazole
Aripiprazole Mylan Pharma 30 mg tablets aripiprazole
Aripiprazole Mylan Pharma 30 mg tabletter er lyserøde, ovale og bikonvekse af 17.1mm i længden, 8,1 mm i bredden, indgraveret med "30" på den ene side.
Aripiprazole Mylan Pharma 30 mg tablets are pink, oval and biconvex of 17.1mm in length, 8.1mm in width, engraved with ‘30’ on one side.
Aripiprazole Mylan Pharma 30 mg tabletter EU/1/15/1005/010
Aripiprazole Mylan Pharma 30 mg tablets
Aripiprazole Mylan Pharma 30 mg tabletter Hver tablet indeholder 30 mg Aripiprazole.
Aripiprazole Mylan Pharma 30 mg tablets Each tablet contains 30 mg of aripiprazole.
Aripiprazole Mylan Pharma 5 mg tabletter
Aripiprazole Mylan Pharma 5 mg tablets
Aripiprazole Mylan Pharma 5 mg tabletter Aripiprazole
Aripiprazole Mylan Pharma 5 mg tablets aripiprazole
Aripiprazole Mylan Pharma 5 mg tabletter Aripiprazole Mylan Pharma 10 mg tabletter Aripiprazole Mylan Pharma 15 mg tabletter Aripiprazole Mylan Pharma 30 mg tabletter
Aripiprazole Mylan Pharma 5 mg tablets Aripiprazole Mylan Pharma 10 mg tablets Aripiprazole Mylan Pharma 15 mg tablets Aripiprazole Mylan Pharma 30 mg tablets Aripiprazole
Aripiprazole Mylan Pharma 5 mg tabletter EU/1/15/1005/001
Aripiprazole Mylan Pharma 5 mg tablets
Aripiprazole Mylan Pharma 5 mg tabletter Hver tablet indeholder 5 mg Aripiprazole.
Aripiprazole Mylan Pharma 5 mg tablets Each tablet contains 5 mg of aripiprazole.
Aripiprazole Mylan Pharma anvendes til patienter over 15 år, bipolar lidelse type I, en psykisk sygdom, hvor patienterne skiftevis har episoder med abnormt højt humør (maniske episoder) og perioder med normalt humør.
Aripiprazole Mylan Pharma is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazole Mylan Pharma er effektiv i dosisområdet 10-30 mg/dag.
Aripiprazole is effective in a dose range of 10 to 30 mg/day.
Aripiprazole Mylan Pharma ‐tabletter.indeholder Maltose
Aripiprazole Mylan Pharma tablets contain maltose
Aripiprazole Mylan Pharma-tabletter bruges til at behandle voksne og unge i alderen 13 år og ældre, som lider af en sygdom, der er forbundet med symptomer som fx at føle sig "høj", en overdreven mængde energi, behov for meget mindre søvn end sædvanligt, meget hurtigt tale med et væld af idéer og nogle gange voldsom irritabilitet.
Aripiprazole Mylan Pharma tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Aripiprazole Mylan Pharma-tabletter bruges til at behandle voksne og unge i alderen 15 år og opefter for sygdom, der er forbundet med at høre, se eller føle ting, som ikke er der, mistænksomhed, misopfattelse, usammenhængende tale og opførsel samt nedslået stemningsleje.
It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterized by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness.
Aripiprazole Mylan Pharma1 aripiprazol
Aripiprazole Mylan Pharma1 aripiprazole
Aripiprazole Mylan Pharma10mg tabletter Aripiprazole
Aripiprazole Mylan Pharma 10 mg tablets aripiprazole
Aripiprazole og andre antipsykotika bør anvendes med forsigtighed hos patienter med risiko for aspirationspneumoni.
Aripiprazole and other antipsychotic active substances should be used cautiously in patients at risk for aspiration pneumonia.
Aripiprazole Sandoz 10 mg tabletter aripiprazol
Aripiprazole Sandoz 10 mg tablets aripiprazole
Aripiprazole Sandoz 10 mg tabletter er lyserøde, plettede, runde tabletter med en omtrentlig diameter på 6,0 mm, præget med ”SZ” på den ene side og med ”446” på den anden side.
Aripiprazole Sandoz 10 mg tablets are pink coloured, mottled, round shaped tablets, with an approximate diameter of 6.0 mm, debossed with “SZ” on one side and “446” on the other side.
Aripiprazole Sandoz 15 mg tabletter aripiprazol
Aripiprazole Sandoz 15 mg tablets aripiprazole
Aripiprazole Sandoz 15 mg tabletter er gule, plettede, runde tabletter med en omtrentlig diameter på 7,0 mm, præget med ”SZ” på den ene side og med ”447” på den anden side.
Aripiprazole Sandoz 15 mg tablets are yellow coloured, mottled, round shaped tablets, with an approximate diameter of 7.0 mm, debossed with “SZ” on one side and “447” on the other side.
Aripiprazole Sandoz 20 mg tabletter aripiprazol
Aripiprazole Sandoz 20 mg tablets aripiprazole
Aripiprazole Sandoz 20 mg tabletter er hvide, runde tabletter med en omtrentlig diameter på 7,8 mm, præget med ”SZ” på den ene side og med ”448” på den anden side.
Aripiprazole Sandoz 20 mg tablets are white coloured, round shaped tablets, with an approximate diameter of 7.8 mm, debossed with “SZ” on one side and “448” on the other side.
Aripiprazole Sandoz 30 mg tabletter aripiprazol
Aripiprazole Sandoz 30 mg tablets aripiprazole
Aripiprazole Sandoz 30 mg tabletter er lyserøde, plettede, runde tabletter med en omtrentlig diameter på 9,0 mm, præget med ”SZ” på den ene side og med ”449” på den anden side.
Aripiprazole Sandoz 30 mg tablets are pink coloured, mottled, round shaped tablets, with an approximate diameter of 9.0 mm, debossed with “SZ” on one side and “449” on the other side.
Aripiprazole Sandoz 5 mg tabletter
Aripiprazole Sandoz 5 mg tabletsLactose monohydrate Maize starch
Aripiprazole Sandoz 5 mg tabletter aripiprazol
Aripiprazole Sandoz 5 mg tablets aripiprazole
Aripiprazole Sandoz 5 mg, 10 mg, 15 mg, 30 mg tabletter
Aripiprazole Sandoz 5 mg, 10 mg, 15 mg, 30 mg tablets
Aripiprazole Sandoz anvendes til patienter over 15 år, bipolar lidelse type I, en psykisk sygdom, hvor patienterne skiftevis har episoder med abnormt højt humør (maniske episoder) og perioder med normalt humør.
Aripiprazole Sandoz is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazole Sandoz er effektiv i dosisområdet 10-30 mg/dag.
Aripiprazole Sandoz is effective in a dose range of 10 to 30 mg/day.
Aripiprazole Sandoz-tabletter bruges til at behandle voksne og unge i alderen 13 år og ældre, som lider af en sygdom, der er forbundet med symptomer som fx at føle sig "høj", en overdreven mængde energi, behov for meget mindre søvn end sædvanligt, meget hurtigt tale med et væld af idéer og nogle gange voldsom irritabilitet.
Aripiprazole Sandoz tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Aripiprazole Sandoz-tabletter bruges til at behandle voksne og unge i alderen 15 år og opefter for sygdom, der er forbundet med at høre, se eller føle ting, som ikke er der, mistænksomhed, misopfattelse, usammenhængende tale og opførsel samt nedslået stemningsleje.
It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness.
Aripiprazole Sandoz-tabletter indeholder det aktive stof aripiprazol, som tilhører en gruppe af lægemidler, der kaldes antipsykotika.
Aripiprazole Sandoz tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Aripiprazole Sandoz-tabletter indeholder lactose
Aripiprazole Sandoz tablets contain lactose
Aripiprazole som tillægsbehandling viste superioritet i forhold til placebo for det sekundære endepunkt CGI-BP Severity of Illness score (mani).
Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI-BP Severity of Illness score (mania).
Aripiprazole udskilles i human mælk.
Aripiprazole is excreted in human milk.
Aripiprazole udviste statistisk overlegen virkning sammenlignet med placebo på Aberrant Behaviour Checklist Irritability-underskalaen.
Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale.
Aripiprazole viser antagonistiske egenskaber i dyremodeller med dopaminerg hyperaktivitet og agonistiske egenskaber i dyremodeller med dopaminerg hypoaktivitet.
Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity.
Aripiprazole viser også moderat bindingsaffinitet for serotonin-reuptake site og ingen væsentlig affinitet for muscarine receptorer.
Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors.
Aripiprazole Zentiva anvendes til patienter over 15 år, bipolar lidelse type I, en psykisk sygdom, hvor patienterne skiftevis har episoder med abnormt højt humør (maniske episoder) og perioder med normalt humør.
Aripiprazole Zentiva is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazoleer den dominerende lægemiddelhalvdel ved systemisk cirkulation.
Aripiprazole is the predominant medicinal product moiety in systemic circulation.
Aripiprazols virkning blev undersøgt hos pædiatriske patienter med Tourettes syndrom (aripiprazol: n = 99, placebo: n = 44) i et randomiseret, dobbeltblindet, placebokontrolleret 8-ugers studie med et vægtbaseret fastdosisdesign inden for et dosisområde på 5-20 mg/dag med en startdosis på 2 mg.
The efficacy of aripiprazole was studied in paediatric subjects with Tourette’s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg.
ARISTOTLE STUDIET
ARISTOTLE STUDY
Arixtra 1,5 mg/0,3 ml injektionsvæske fondaparinux Na
Arixtra 1.5 mg/0.3 ml injection fondaparinux Na
Arixtra 1,5 mg/0,3 ml injektionsvæske, opløsning fondaparinuxnatrium
Arixtra 1.5 mg/0.3 ml solution for injection fondaparinux sodium
Arixtra 10 mg/0,8 ml injektionsvæske fondaparinux Na
Arixtra 10 mg/0.8 ml injection fondaparinux Na
Arixtra 10 mg/0,8 ml injektionsvæske, opløsning fondaparinuxnatrium
Arixtra 10 mg/0.8 ml solution for injection fondaparinux sodium
Arixtra 2,5 mg/0,5 ml injektionsvæske fondaparinux Na
Arixtra 2.5 mg/0.5 ml injection fondaparinux Na
Arixtra 2,5 mg/0,5 ml injektionsvæske, opløsning fondaparinuxnatrium
Arixtra 2.5 mg/0.5 ml solution for injection fondaparinux sodium
Arixtra 5 mg/0,4 ml injektionsvæske fondaparinux Na
Arixtra 5 mg/0.4 ml injection fondaparinux Na
Arixtra 5 mg/0,4 ml injektionsvæske, opløsning fondaparinuxnatrium
Arixtra 5 mg/0.4 ml solution for injection fondaparinux sodium
Arixtra 7,5 mg/0,6 ml injektionsvæske fondaparinux Na
Arixtra 7.5 mg/0.6 ml injection fondaparinux Na
Arixtra 7,5 mg/0,6 ml injektionsvæske, opløsning fondaparinuxnatrium
Arixtra 7.5 mg/0.6 ml solution for injection fondaparinux sodium
Arixtra anbefales ikke til patienter, som skal have foretaget visse former for operationer, som skal udvide blodkarrene i hjertet.
Arixtra is not recommended in patients who are about to undergo certain types of operations to unblock the heart’s blood vessels.
Arixtra behøves ikke at blive opbevaret i køleskab.
Arixtra does not have to be kept in the fridge.
Arixtra behøves ikke at blive opbevaret i køleskab.
Arixtra does not need to be kept in the fridge.
Arixtra er en klar og farveløs injektionsvæske.
Arixtra is a clear and colourless solution for injection.
Arixtra er en klar og farveløs til svag gul injektionsvæske.
Arixtra is a clear and colourless to slightly yellow solution for injection.
Arixtra er et lægemiddel, som hjælper med at forhindre, at der dannes blodpropper i blodkarrene (et antitrombotisk middel).
Arixtra is a medicine that treats or helps to prevent blood clots from forming in the blood vessels
Arixtra er et lægemiddel, som hjælper med til at forhindre, at der dannes blodpropper i blodkarrene (et antitrombotisk middel).
Arixtra is a medicine that helps prevent blood clots from forming in the blood vessels (an antithrombotic agent).
Arixtra fås i pakninger med 2, 7, 10 og 20 fyldte injektionssprøjter.
Arixtra 10 mg/0.8 ml is available in pack sizes of 2, 7, 10 and 20 pre-filled syringes.
Arixtra fås i pakninger med 2, 7, 10 og 20 fyldte injektionssprøjter.
Arixtra 5 mg/0.4 ml is available in pack sizes of 2, 7, 10 and 20 pre-filled syringes.
Arixtra fås i pakninger med 2, 7, 10 og 20 fyldte injektionssprøjter.
Arixtra 7.5 mg/0.6 ml is available in pack sizes of 2, 7, 10 and 20 pre-filled syringes.
Arixtra injiceres under huden (subkutant) i en hudfold nederst på maven.
Arixtra is given by injection under the skin (subcutaneously) into a skin fold of the lower abdominal area.
Arixtra må ikke injiceres i en muskel.
Do not inject Arixtra into muscle.
arkoidose (sjælden).
arcoidosis (rare).
arkoidose1) vaskulitis
arcoidosis1), vasculitis
arkoidose1) vaskulitis
sarcoidosis1), vasculitis
Arm B bival +GP IIb/IIIa- inhibitor (N=2.924)
Arm B bival +GP IIb/IIIa inhibitor (N=2,924)
Arm B bival +GP IIb/IIIa- inhibitor (N=4.604)
Arm B bival +GP IIb/IIIa inhibitor (N=4,604)
Arme: Bagsiden af overarmen bør bruges.
ack of the upper arm should be used.
Armen sover
Pins and needles
Armisarte 25 mg/ml koncentrat til infusionsvæske, opløsning.
Armisarte 25 mg/ml concentrate for solution for infusion
Armisarte er en klar, farveløs til svagt gulligt eller gul-grønlig opløsning.
Armisarte is a clear, colourless to slightly yellowish or yellow-greenish solution.
Armisarte er et "hybridt lægemiddel".
Armisarte is a ‘hybrid medicine’.
Armisarte skal administreres som intravenøs infusion over 10 minutter på den første dag i hver 21- dages serie.
Armisarte should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
armodafinil, modafinil (til behandling af søvnighed)
armodafinil, modafinil (to treat sleepiness)
Armsmerter, stivhed i bevægeapparatet
Arm pain, Musculoskeletal stiffness
ARROW PK
Substudy Part 1
Arsen i TRISENOX udskilles i mælken.
The arsenic in TRISENOX passes into breast milk.
Arsensammensætninger påfører kromosom-afvigelser og morfologiske ændringer af pattedyrsceller in vitro og in vivo.
Arsenic compounds induce chromosomal aberrations and morphological transformations of mammalian cells in vitro and in vivo.
Arsentrioxid
Arsenic trioxide
Arsentrioxid fremkalder morfologiske ændringer og deoxyribonukleinsyre (DNA)-fragmenteringsegenskaber, som er karakteristisk for apoptose ved NB4-humane promyelocyt leukæmi-celler in vitro.
Arsenic trioxide causes morphological changes and deoxyribonucleic acid (DNA) fragmentation characteristic of apoptosis in NB4 human promyelocytic leukaemia cells in vitro.
Arsentrioxid skader og nedbryder også fusionsproteinet Promyelocytisk leukæmi/Retinoinsyrereceptor-alfa (PML/RAR-alfa).
Arsenic trioxide also causes damage or degradation of the fusion protein Pro-Myelocytic Leukaemia/Retinoic Acid Receptor-alpha (PML/RAR alpha).
ART fastlægges ved afslutning af produktionen. (GBq: GigaBecquerel er måleenheden for radioaktivitet).
The ART is defined as the end of production. (GBq: GigaBecquerel is the unit in which radioactivity is measured).
ART-erfarne patienter – dosering en gang dagligt
ART-experienced patients – once daily dosing
ART-erfarne patienter–dosering en gang dagligt
ART-experienced patients – once daily dosing
ART-erfarne pædiatriske patienter (3 til 17 år og legemsvægt mindst 15 kg)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 15 kg)
ART-erfarne pædiatriske patienter (3 til 17 år og legemsvægt mindst 15 kg)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 15 kilograms)
ART-erfarne pædiatriske patienter (3 til 17 år og legemsvægt mindst 40 kg)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg)
ART-erfarne pædiatriske patienter i alderen 3 til < 6 år
ART-experienced paediatric patients from the age of 3 to < 6 years
ART-erfarne pædiatriske patienter i alderen 6 til < 18 år med legemsvægt mindst 20 kg DELPHI er et åben label fase II studie, hvor farmakokinetikken, sikkerheden, tolerabiliteten og effekten af PREZISTA med lavdosis ritonavir blev undersøgt hos 80 ART-erfarne hiv-1-smittede pædiatriske patienter i alderen 6 til 17 år og med en vægt på mindst 20 kg.
ART-experienced paediatric patients from the age of 6 to < 18 years, and weighing at least 20 kg DELPHI is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of PREZISTA with low dose ritonavir in 80 ART-experienced HIV-1 infected paediatric patients aged 6 to 17 years and weighing at least 20 kg.
ART-erfarne, lopinavir-naive patienter, på analysen efter 48 uger i fase III-studiet ODIN hos ART-erfarne patienter uden DRV-RAMs og på analysen af 96-ugers-data fra fase IIb-studierne POWER 1 og 2 hos ART-erfarne patienter med høj grad af PI-resistens.
ART-experienced lopinavir naïve patients, on the 48 week analysis of the Phase III trial ODIN in ART-experienced patients with no DRV-RAMs, and on the analyses of 96 weeks data from the Phase IIb trials POWER 1 and 2 in ART-experienced patients with high level of PI resistance.
ART-naive
ART-naïve
ART-naive eller PI-naive patienter
ART-naïve or PI-naïve patients
ART-naive pædiatriske patienter (3 til 17 år med legemsvægt på mindst 15 kg)
ART-naïve paediatric patients (3 to 17 years of age and weighing at least 15 kg)
ART-naive pædiatriske patienter (3 til 17 år og legemsvægt mindst 15 kg)
ART-naïve paediatric patients (3 to 17 years of age and weighing at least 15 kg)
ART-naive pædiatriske patienter (3 til 17 år og legemsvægt mindst 15 kg)
ART-naïve paediatric patients (3 to 17 years of age and weighing at least 15 kilograms)
ART-naive pædiatriske patienter (3 til 17 år og legemsvægt mindst 40 kg)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg)
ART-naive pædiatriske patienter (3 til 17 år og legemsvægt mindst 40 kg)
ART-naïve paediatric patients (3 to 17 years of age and weighing at least 40 kg)
ART-naive pædiatriske patienter (3 år til 17 år og legemsvægt mindst 40 kg)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg)
ART-naive pædiatriske patienter (under 3 år eller legemsvægt mindre end 15 kg)
ART-naïve paediatric patients (less than 3 years of age or less than 15 kg body weight)
ART-naive pædiatriske patienter (under 3 år eller legemsvægt under 15 kg)
ART-naïve paediatric patients (less than 3 years of age or less than 15 kg body weight)
ART/TYPE: Hætteglas af glas
NATURE/TYPE: Glass vial
ART: {DD/MM/ÅÅÅÅ 12:00 CET }
ART: {DD/MM/YYYY 12:00 CET }
ART: {DD/MM/ÅÅÅÅ} {hh:mm} CET
ART: {DD/MM/YYYY} {hh:mm} CET
artemeter
artemether
Artemeter/ lumefantrin
Artemether/ Lumefantrine
artemether AUC ↓ 16 % artemether Cmin ↔ artemether Cmax ↓ 18 % dihydroartemisinin AUC ↓ 18 % dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18 % lumefantrin AUC ↑ 175 % lumefantrin Cmin ↑ 126 % lumefantrin Cmax ↑ 65 % darunavir AUC ↔ darunavir Cmin ↓ 13 % darunavir Cmax ↔
artemether AUC ↓ 16% artemether Cmin ↔ artemether Cmax ↓ 18% dihydroartemisinin AUC ↓ 18% dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18% lumefantrine AUC ↑ 175% lumefantrine Cmin ↑ 126% lumefantrine Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔
artemether AUC ↓ 16 % artemether Cmin ↔ artemether Cmax ↓ 18 % dihydroartemisinin AUC ↓ 18 % dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18 % lumefantrine AUC ↑ 175 % lumefantrin Cmin ↑ 126 % lumefantrin Cmax ↑ 65 % darunavir AUC ↔ darunavir Cmin ↓ 13 % darunavir Cmax ↔
artemether AUC ↓ 16% artemether Cmin ↔ artemether Cmax ↓ 18% dihydroartemisinin AUC ↓ 18% dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18% lumefantrine AUC ↑ 175% lumefantrine Cmin ↑ 126% lumefantrine Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔
artemether,
caution is recommended when
artemether,
dihydroartemisinin, or
Artemether/ lumefantrin
Artemether/Lumefantrine
artemether/lumefantrin (et kombinationspræparat til behandling af malaria)
Artemether/lumefantrine (a combination medicine to treat malaria).
Artemether/lumefantrin (malariamiddel).
artemether/lumefantrine (a medicine to treat malaria)
artemether/lumefantrin-
Antimalarials
artemether/lumefantrin-tabletter
Dihydroartemisinin:
Artemether/lumefantrin/ tenofovirdisoproxilfumarat
Artemether/Lumefantrine/Tenofovir disoproxil fumarate
Artemether/lumefantrin/efavirenz (20/120 mg tablet, 6 doser hver med 4 tabletter i 3 dage/600 mg q.d.)
Artemether/Lumefantrine/Efavirenz (20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600 mg q.d.)
Artemether/lumefantrin/emtricitabin
Artemether/Lumefantrine/Emtricitabine
Artemether:
Bupropion/Efavirenz
Artenimol blev observeret til at have et lille fordelingsvolumen hos mennesker (0,8 l/kg, CV 35,5 %).
Artenimolwas observed to have a small volume of distribution in humans (0.8 l/kg; CV 35.5%).
Artenimol elimineres via metabolismen (hovedsageligt glukurokonjugation).
Artenimol is eliminated by metabolism (mainly glucuroconjugation).
Artenimol konverteres hovedsageligt til α-artenimol-β-glukuronid (α-artenimol-G).
Artenimol is principally converted to α- artenimol-β-glucuronide (α- artenimol-G).
arter
species
Arter for hvilke erhvervet resistens kan blive et problem:
Species for which acquired resistance may be a problem:
Arter hvor erhvervet resistens kan være et problem
Species for which acquired resistance may be a problem